Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.54 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27617548 | 0.98 | EPHX1 (0.57) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 | |
| Ammonia Solution, Strong SCHEMBL28754528 | 0.98 | EPHX1 (0.57) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 | |
| SCHEMBL253022 | 0.98 | EPHX1 (0.56) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 | |
| SCHEMBL372894 | 0.96 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 | |
| SCHEMBL153838 | 0.96 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 | |
| SCHEMBL146327 | 0.96 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 | |
| SCHEMBL150597 | 0.96 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 | |
| SCHEMBL148882 | 0.96 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 | |
| SCHEMBL144546 | 0.96 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 | |
| SCHEMBL149423 | 0.96 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2PLA2G2ACASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2063914-B1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | ZENTIVA KS (CZ) | 2018-12-26 | — | — | EP | disclosed |
| US-8603990-B2 | Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation | ZENTIVA K.S. (CS) | 2013-12-10 | — | — | US | disclosed |
| US-20090306004-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | ZENTIVA K.S. (CZ) | 2009-12-10 | — | — | US | disclosed |
| EP-2063914-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | Zentiva, k.s. (CZ) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008034391-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | ZENTIVA, A.S. (CZ) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306004-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | DNPEP, HDGF, LNPEP | EPHX1 2659/4885ZDHHC20 2599/4885ZDHHC2 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.